BiVACOR, Inc.

“People think it’s the patients who are benefiting most from this technology. They’re not. It’s the family that’s benefiting most.” – Daniel Timms, Founder & CTO of BiVACOR Learn more about our founder's inspiring story and dedicated vision to bring the BiVACOR total artificial heart (TAH) to people in need, as we prepare for our upcoming first-in-human bridge-to-transplant procedures. https://lnkd.in/eAu6F_C3 The Sydney Morning Herald  The Age amanda hooton #HeartFailure #HeartDisease #Cardiology #MedTech #HealthTech #MedicalDevices

"The BiVACOR TAH is the first device designed to replace an entire heart with a long-term solution. Nobody has done that before." – Daniel Timms, Founder & CTO of BiVACOR In the coming months, our BiVACOR total artificial heart (TAH) will undergo evaluation as a bridge to heart transplant for biventricular heart failure patients. Dive into the Engineers Australia article below to discover how the BiVACOR TAH came to fruition, and visit our website (www.bivacor.com) to learn more! Caroline Riches https://lnkd.in/e5KYrJYi #HeartFailure #HeartDisease #Cardiology #MedTech #HealthTech #MedicalDevices

On this episode of 'Inside the Studio', Joseph G. Rogers, M.D., president & CEO of The Texas Heart Institute, talks with our Chief Medical Officer, Dr. William Cohn, about the potential of the BiVACOR® Total Artificial Heart (TAH) to revolutionize treatment for patients with severe biventricular heart failure. We're proud to partner with The Texas Heart Institute and other leading heart transplant institutions on our upcoming first-in-human Early Feasibility Studies. Learn more at https://bivacor.com/ #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices https://lnkd.in/dsb_xuU8

Watch as our Chief Medical Officer, William Cohn, presented the BiVACOR® Total Artificial Heart (TAH) at The Texas Heart Institute's Cardiology Grand Rounds. We're proud to partner with The Texas Heart Institute and other leading heart transplant institutions on our upcoming first-in-human Early Feasibility Studies.   Our novel TAH uses magnetic levitation (MAGLEV) technology, the same principle used in high-speed trains, the design includes left and right vanes positioned on a common rotor to form the only moving part, a magnetically suspended double-sided centrifugal impeller. Even though there are no valves or flexing ventricle chambers, the pulsatile outflow is made possible by rapidly cycling the rotational speed of the impeller. The non-contact suspension provides large blood gaps minimizing blood trauma and eliminating mechanical wear to offer a durable, reliable, and biocompatible heart replacement.   Learn more at https://bivacor.com/   #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices

On Monday at #THT2024, BiVACOR® founder & CTO Daniel Timms presented our novel Total Artificial Heart (TAH). What is the BiVACOR TAH? 👇 The BiVACOR Total Artificial Heart is designed as the first long-term therapy dedicated to patients with severe biventricular heart failure. It is an implantable total artificial heart based on rotary blood pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of providing enough cardiac output to an adult male undergoing exercise. Using magnetic levitation (MAGLEV) technology, the same principle used in high-speed trains, the design includes left and right vanes positioned on a common rotor to form the only moving part, a magnetically suspended double-sided centrifugal impeller. Even though there are no valves or flexing ventricle chambers, the pulsatile outflow is made possible by rapidly cycling the rotational speed of the impeller. The non-contact suspension provides large blood gaps minimizing blood trauma and eliminating mechanical wear to offer a durable, reliable, and biocompatible heart replacement. View the slides from THT at TCTMD here: https://lnkd.in/e6FAx5bQ Please note that a free registration is required to view. #tht #tht24 #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices

Will you be at THT in Boston March 4 - 6? Daniel Timms, Founder & CTO of BiVACOR®, is presenting the company’s revolutionary Total Artificial Heart (TAH). Daniel’s session occurs during Monday’s Concurrent Session 2: 'LVADs: Pipeline of New Pumps' at 2:50 PM EST, titled ‘BiVACOR: A Novel, Magnetically Levitated Rotary Pump-Based TAH'.  Check back for a link to the recording if you miss it.

A great news article on Daniel Timms, PhD, and the BiVACOR Artificial Heart. https://lnkd.in/etpyuitx

Don't miss this great article about Founder Daniel Timms, PhD, from the Sydney Morning Herald. https://lnkd.in/gfBQ65-z

In case you missed it - Dec. 27, 2023 - BiVACOR® Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors https://lnkd.in/exuTUAM9

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart https://lnkd.in/dMGu8Srq